azd6234
Small moleculeexperimental
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 20, 2022 (NCT05511025)
Timeline
Indications
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07220954 | Phase 1 | Nov 10, 2025 | AstraZeneca, Quotient |
| NCT07017179 | Phase 2 | May 20, 2025 | AstraZeneca |
| NCT06851858 | Phase 2 | Mar 12, 2025 | AstraZeneca |
| NCT06845813 | Phase 1 | Feb 24, 2025 | AstraZeneca |
| NCT06862791 | Phase 2 | Feb 18, 2025 | AstraZeneca |
| NCT06595238 | Phase 2 | Oct 1, 2024 | AstraZeneca |
| NCT06132841 | Phase 1 | Nov 13, 2023 | AstraZeneca, Parexel |
| NCT05511025 | Phase 1 | Sep 20, 2022 | AstraZeneca |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 8 | 8 | 2 | 2022 |
| Parexel | For profit | 1 | 0 | 1 | 2023 |
| Quotient | For profit | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1